Nuo Therapeutics Business Summary

Nuo Therapeutics, Inc. (AURX) is a commercial-stage medical device company specializing in regenerative therapies for the advanced wound care market. The company generates revenue primarily through transactional product sales of its flagship Aurix System, a point-of-care technology that processes a patient’s autologous blood into a biodynamic hematogel (platelet-rich plasma) to treat chronic wounds such as diabetic foot ulcers and pressure ulcers. Operating within the $3.6 billion North American advanced wound care segment, Nuo leverages a 2021 CMS National Coverage Determination (NCD) to drive adoption across hospital outpatient clinics and private physician practices. The company competes directly with established regenerative medicine players such as MiMedx Group, AVITA Medical, and Sanara MedTech, positioning itself as a specialized provider of cost-effective, autologous blood-based healing solutions. Leadership is spearheaded by David E. Jorden, who has served as Chief Executive Officer and Chief Financial Officer since 2016; Jorden is a CPA with a deep background in corporate finance and restructuring, having led the company through its strategic pivot and 2021 commercial relaunch. He is supported by Dr. Peter A. Clausen, the Chief Operating Officer and Chief Scientific Officer, a Ph.D. and former founding member of Marligen Bioscience with extensive expertise in genomic analysis and biotechnology R&D. The company’s strategic direction is further influenced by a seasoned board and significant stakeholders, including Independent Director Scott M. Pittman and major passive investor Paul Anthony Jacobs, both of whom participated in a $1.6 million debt financing round in January 2026 to bolster working capital for continued commercial expansion.